DrugChatter: Who owns dilaudid company?
Who makes Dilaudid (hydromorphone) and who owns the brand? Dilaudid is a brand name for hydromorphone, an opioid pain medicine…. https://www.Drugchatter.com/chat/53035/who-owns-dilaudid-company/
Who makes Dilaudid (hydromorphone) and who owns the brand? Dilaudid is a brand name for hydromorphone, an opioid pain medicine…. https://www.Drugchatter.com/chat/53035/who-owns-dilaudid-company/
What is the Chinese (CN) name for Ozempix? The provided information doesnt include any details about a product named… https://www.Drugchatter.com/chat/36985/ozempix-chinese-name/
Which Chinese pharmaceutical companies are investing in AI? A number of Chinese drugmakers have been putting money into… https://www.Drugchatter.com/chat/50765/chinese-pharmsutical-company-investing-in-ai/
DrugChatter: Chinese pharmsutical company investing in ai? Read Post »
Is Gleevec (imatinib) among the most expensive drugs? Gleevec (imatinib) is widely known as an expensive cancer medicine,… https://www.Drugchatter.com/chat/31710/is-gleevec-the-most-expensive-drug/
DrugChatter: Is gleevec the most expensive drug? Read Post »
Branded generics vs. commodity generics: the quiet battle for trustand why its winning market share.
In generic drugs, the conversation is usually about price. But the market is increasingly telling a different story: when two products are therapeutica…
Branded Generics vs. Commodity Generics: How Brand Trust Wins Market Share Read Post »
Pharmas next competitive edge isnt just scienceits timing.
In blockbuster drug markets, the race often looks like a clinical one: trials, endpoints, approvals. But the real advantage frequently comes earlierat the moment a company decides when to file,…
Dont Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In Massachusetts, a quick drug patent check can turn into a costly surpriseespecially when youre underwriting market entry, licensing rights, or evaluating pipeline ri…
Don’t Get Blind-Sided: The Critical Drug Patent Mistakes to Avoid in M&A Due Diligence Read Post »
Post-approval patents are supposed to be the fine print that keeps innovators protected after launch. But in practice, theyre often the hidden risk map that determines whether your product stays on the marketor gets boxed in by litigation, settlements,…
Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…
Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
Most people think drug exclusivity is a simple countdown from a single dateoften framed as 20 years. But in practice, the market life of a drug is shaped by a messy stack of legal rig…
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
Get new actionable insights and updates from BiotechBlog